157 related articles for article (PubMed ID: 37122915)
1. Efficacy and safety of preoperative chemoradiotherapy with S-1 for advanced rectal cancer: a phase II study.
Ushigome M; Funahashi K; Kaneko T; Kagami S; Yoshida K; Miura Y; Koda T; Nagashima Y; Kurihara A; Terahara A
Rep Pract Oncol Radiother; 2023; 28(1):36-46. PubMed ID: 37122915
[TBL] [Abstract][Full Text] [Related]
2. Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan.
Chao JY; Wang HM; Chiang FF; Lin JC; Chang CF; Lin JF; Yeh HL
J Chin Med Assoc; 2014 Mar; 77(3):128-32. PubMed ID: 24398439
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
Matsuhashi N; Takahashi T; Tanaka C; Yawata K; Yamada M; Iwata Y; Kiyama S; Mizutani C; Tajima JY; Ishihara T; Yoshida K
Anticancer Res; 2021 Dec; 41(12):6247-6257. PubMed ID: 34848480
[TBL] [Abstract][Full Text] [Related]
6. A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial.
Inomata M; Akagi T; Nakajima K; Etoh T; Tahara K; Matsumoto T; Ogawa T; Fujii K; Shiromizu A; Kitano S
Mol Clin Oncol; 2016 Apr; 4(4):510-514. PubMed ID: 27073652
[TBL] [Abstract][Full Text] [Related]
7. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
[TBL] [Abstract][Full Text] [Related]
8. Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes?
Sun Myint A; Mukhopadhyay T; Ramani VS; Perkins K; Snee AJ; Jelley F; Wong H; Lee CD
Colorectal Dis; 2010 Aug; 12 Suppl 2():30-6. PubMed ID: 20618365
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-3.
Serizawa A; Kuramochi H; Taniguchi K; Ota M; Katagiri S; Yamada T; Kotake S; Ito S; Suzuki K; Yamamoto M
Med Oncol; 2021 Jul; 38(9):98. PubMed ID: 34302539
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
11. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Itano O; Takemura Y; Kishida N; Tamagawa E; Shinozaki H; Ikeda K; Urakami H; Ei S; Hayatsu S; Suzuki K; Sakuragawa T; Ishii M; Shito M; Aiura K; Fujisaki H; Takano K; Matsui J; Minagawa T; Shinoda M; Kitago M; Abe Y; Yagi H; Oshima G; Hori S; Kitagawa Y
BMC Cancer; 2020 Jul; 20(1):688. PubMed ID: 32703191
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis.
Nakagawa R; Inoue Y; Ohki T; Kaneko Y; Maeda F; Yamamoto M
World J Surg Oncol; 2017 May; 15(1):112. PubMed ID: 28566093
[TBL] [Abstract][Full Text] [Related]
13. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer.
Tei M; Noura S; Ohue M; Kitakaze M; Takahashi H; Miyoshi N; Uemura M; Mizushima T; Murata K; Doki Y; Eguchi H
Int J Clin Oncol; 2021 Nov; 26(11):2046-2052. PubMed ID: 34318389
[TBL] [Abstract][Full Text] [Related]
16. [Short-term efficacy comparison between preoperative three dimensional conformal radiotherapy and volumetric modulated arc therapy concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma].
Xiao L; Yu X; Zhu Y; Xiao W; Zeng Z; Liu M; Zhang R; Gao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jul; 19(7):769-75. PubMed ID: 27452754
[TBL] [Abstract][Full Text] [Related]
17. ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group.
Fleischmann M; Diefenhardt M; Nicolas AM; Rödel F; Ghadimi M; Hofheinz RD; Greten FR; Rödel C; Fokas E;
Clin Transl Radiat Oncol; 2022 May; 34():99-106. PubMed ID: 35449546
[TBL] [Abstract][Full Text] [Related]
18. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab for locally advanced resectable rectal adenocarcinoma.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A; Akiba T; Kawada S
Oncology; 2015; 88(1):49-56. PubMed ID: 25277532
[TBL] [Abstract][Full Text] [Related]
20. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
